Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 766 to 780 of 1773 results for patient safety

  1. Sarilumab for moderate to severe rheumatoid arthritis (TA485)

    Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.

  2. Thoracoscopic aortopexy for severe primary tracheomalacia (HTG156)

    Evidence-based recommendations on thoracoscopic aortopexy for severe primary tracheomalacia. This involves attaching the aorta to the sternum with sutures, using special instruments through small cuts in the chest (keyhole surgery).

  3. Medicines management for people receiving social care in the community (QS171)

    This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have the medicines support they need. It describes high-quality care in priority areas for improvement.

  4. Patient experience in adult NHS services (QS15)

    This quality standard covers improving the quality of the patient experience for people who use adult NHS services. It describes high-quality care in priority areas for improvement.

  5. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    This guide outlines the main elements of the interim process and methods for the NICE clinical guideline updates using standing committees pilot programme, including details of the Clinical Guidelines Updates committee, which were agreed by the NICE Board in September 2013

  6. Making decisions using NICE guidelines

    People have the right to be able to make informed decisions about their care. Our guidance should be taken into account when making decisions with them.

  7. Needle-free arterial non-injectable connector (MIB85)

    NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .

  8. Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

    Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

  9. Catheterless oesophageal pH monitoring (HTG121)

    Evidence-based recommendations on catheterless oesophageal pH monitoring. This involves placing a small wireless capsule in the gullet to check the level of acid.

  10. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

    Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.

  11. Implantation of a duodenal–jejunal bypass liner for managing type 2 diabetes (HTG371)

    Evidence-based recommendations on implantation of a duodenal-jejunal bypass liner for managing type 2 diabetes. This involves attaching a liner as a barrier between food and the upper part of the bowel, with the aim of lowering blood sugar levels.

  12. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  13. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy (TA117)

    Evidence-based recommendations on cinacalcet (Mimpara) for treating secondary hyperparathyroidism in people with end-stage renal disease who are on dialysis.

  14. Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (HTG319)

    Evidence-based recommendations on photochemical corneal cross linkage using riboflavin and ultraviolet A for keratoconus. This involves using special eye drops and exposing the eye ultraviolet light, with the aim to strengthen the cornea.

  15. Grenz rays therapy for inflammatory skin conditions (HTG151)

    Evidence-based recommendations on Grenz rays therapy for inflammatory skin conditions. This involves exposing the skin to low-energy, non-penetrative electromagnetic radiation.